Details

Autor(en) / Beteiligte

• Xie, Shihao
• Li, Jiaxin
• Lyu, Fengyuan
• Xiong, Qingming
• Gu, Peng
• Chen, Yuqi
• Chen, Meiling
• Bao, Jingna
• Zhang, Xianglong
• Wei, Rongjuan
• Deng, Youpeng
• Wang, Hongzheng
• Zeng, Zhenhua
• Chen, Zhongqing
• Deng, Yongqiang
• Lian, Zhuoshi
• Zhao, Jie
• Gong, Wei
• Chen, Ye
• Liu, Ke-Xuan
• Duan, Yi
• Jiang, Yong
• Zhou, Hong-Wei
• Chen, Peng

Titel

Novel tripeptide RKH derived from Akkermansia muciniphila protects against lethal sepsis

Ist Teil von

• Gut, 2024-01, Vol.73 (1), p.78-91

Ort / Verlag

England: BMJ Publishing Group Ltd and British Society of Gastroenterology

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• ObjectiveThe pathogenesis of sepsis is complex, and the sepsis-induced systemic proinflammatory phase is one of the key drivers of organ failure and consequent mortality. Akkermansia muciniphila (AKK) is recognised as a functional probiotic strain that exerts beneficial effects on the progression of many diseases; however, whether AKK participates in sepsis pathogenesis is still unclear. Here, we evaluated the potential contribution of AKK to lethal sepsis development.DesignRelative abundance of gut microbial AKK in septic patients was evaluated. Cecal ligation and puncture (CLP) surgery and lipopolysaccharide (LPS) injection were employed to establish sepsis in mice. Non-targeted and targeted metabolomics analysis were used for metabolites analysis.ResultsWe first found that the relative abundance of gut microbial AKK in septic patients was significantly reduced compared with that in non-septic controls. Live AKK supplementation, as well as supplementation with its culture supernatant, remarkably reduced sepsis-induced mortality in sepsis models. Metabolomics analysis and germ-free mouse validation experiments revealed that live AKK was able to generate a novel tripeptide Arg-Lys-His (RKH). RKH exerted protective effects against sepsis-induced death and organ damage. Furthermore, RKH markedly reduced sepsis-induced inflammatory cell activation and proinflammatory factor overproduction. A mechanistic study revealed that RKH could directly bind to Toll-like receptor 4 (TLR4) and block TLR4 signal transduction in immune cells. Finally, we validated the preventive effects of RKH against sepsis-induced systemic inflammation and organ damage in a piglet model.ConclusionWe revealed that a novel tripeptide, RKH, derived from live AKK, may act as a novel endogenous antagonist for TLR4. RKH may serve as a novel potential therapeutic approach to combat lethal sepsis after successfully translating its efficacy into clinical practice.